Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Tandem Diabetes Care, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Legal Action and Investor Rights - Shareholders who purchased Tandem Diabetes Care securities may be entitled to compensation through a class action lawsuit without any out-of-pocket fees [2]. - The Rosen Law Firm is preparing a class action to seek recovery of investor losses related to the misleading information [2]. Group 2: Company Incident and Stock Impact - On August 7, 2025, Tandem Diabetes Care announced a voluntary medical device correction for select t:slim X2 insulin pumps due to a potential speaker-related issue that could lead to insulin delivery discontinuation [3]. - Following this announcement, Tandem Diabetes' stock experienced a significant decline of 19.9% on the same day [3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked highly for settlements since 2013 [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering substantial amounts for clients [4].

Core Viewpoint - Sailfish Royalty Corp. has successfully closed its acquisition of the permitted Mt. Hamilton Gold-Silver Project in Nevada and has entered into a definitive agreement for a five-year gold stream and a subsequent 2% net smelter royalty (NSR) [1][2] Acquisition Details - The acquisition includes a five-year gold stream where Sailfish will receive approximately 341.7 troy ounces of gold monthly at a price equal to 20% of the London Bullion Market Association PM Fix price, with a minimum of US$2,700 and a maximum of US$3,700 per ounce [3] - Sailfish has also acquired the outstanding membership interests of Mt. Hamilton LLC, which owns the property, from a third party [2] Financial Arrangements - To fund the acquisition, Sailfish has entered into a credit agreement for a USD$40 million senior secured bridge term facility with Wexford Capital LP and other guarantors [6][10] - The company will use the Wexford Loan to fund the purchase price for the acquisition and to purchase the Company Interests as a nominee for Mako US [7] Regulatory and Shareholder Approvals - The closing of the Mako Transaction is subject to customary closing conditions, including acceptance from the TSX Venture Exchange and approval from both Sailfish's and Mako's shareholders [4][9] - A special meeting of shareholders is expected to be held by February 2026 to consider the Mako Transaction, requiring a simple majority for approval [13][14] Related Party Transactions - The Mako Transaction is classified as a "related party transaction" due to common control between Mako and Sailfish, necessitating disinterested shareholder approval [9][12] - The Wexford Loan is also considered a related party transaction, but it is deemed to be on reasonable commercial terms [12] Project Status - The Mt. Hamilton Project has all major state and federal permits to begin construction for an open pit, heap leach gold-silver project, and has a current mineral resource estimate [5]

Group 1 - The company, Graycliff Exploration Limited, announced a share consolidation on a one post-consolidation Common Share for every four pre-consolidation Common Shares basis [1] - The consolidation will reduce the number of outstanding Common Shares from 17,609,841 to approximately 4,402,460 [3] - The company has obtained a new CUSIP and ISIN for the shares, and the consolidation is subject to approval by the Canadian Securities Exchange [2] Group 2 - Registered shareholders will receive letters of transmittal and must send their pre-consolidation share certificates to the company's registrar and transfer agent [4] - Graycliff Exploration is focused on mineral exploration, particularly on its 1,468 hectares of land near the historic Shakespeare Gold Mine [5] - The company has drilled over 12,500 meters at the Shakespeare Project, with visible gold identified in multiple holes [5]

Core Insights - Clear Blue Technologies International Inc. reported significant financial growth in Q3 2025, with new bookings increasing by 682% and revenue rising by 158% compared to Q3 2024 [3] - The company anticipates stronger demand in the telecom sector due to larger-scale customers executing their 2026 roll-out plans [2] - Clear Blue has secured a repeat order worth $1.5 million from iSat Africa, expected to ship over the next two quarters [3] Financial Performance - Q3 2025 new bookings were $745,175, up from $95,277 in Q3 2024 [3] - Q3 2025 revenue reached $953,972, compared to $369,297 in Q3 2024, driven by increased North American lighting activity [3] - Recurring revenue for Q3 2025 was $164,032, a 60% increase from $102,686 in Q3 2024 [3] - Gross Profit for Q3 2025 was $352,574, an increase of 108% from $169,323 in Q3 2024, with a gross margin percentage of 37% [3] - Year-to-date bookings as of September 30, 2025, were $4,203,699, a 192% increase from $1,441,444 in the same period in 2024 [3] - For the nine months ended September 30, 2025, revenue was $3,139,229, a 43% increase from $2,192,540 in the previous period [3] Management Commentary - The CEO of Clear Blue expressed confidence in achieving improved financial results in the coming year through revenue growth with key commercial partners and ongoing expense management [2][4] - The company identified an opportunity to reduce operating expenses by approximately $200,000 in 2026 through cloud software license cost optimizations [3] Private Placement - Clear Blue closed an initial tranche of a non-brokered private placement, raising $300,000, with plans for further tranches [4][5] - The offering involved issuing 6,000,000 units at a price of $0.05 per unit, with each unit consisting of one common share and one warrant [5] - The net proceeds from the offering are intended for sales, business development, and working capital [5]

Core Insights - Quantum eMotion Corp. has released its Q3 Financial Statements and Management Discussion and Analysis, highlighting its financial performance and strategic direction [1][3] Financial Performance - The company generated net proceeds of $20.3 million from successful LIFE offerings in the first half of 2025 [2] - During the nine-month period ending September 30, 2025, 15.3 million warrants were exercised, resulting in additional cash proceeds of $6.3 million, leading to a cash balance of $24.7 million at the end of the period [2] Strategic Initiatives - The company is positioned to invest in new opportunities, enhance R&D efforts, and continue its transition to commercialization, which includes increasing its visibility in the USA through the establishment of a subsidiary [2] Stock Option Clarifications - The number of stock options granted to officers and employees was corrected from 3,920,000 to 3,820,000 [4] - Discrepancies were noted in previous news releases regarding the terms of stock options granted to senior officers, with specific cancellations and adjustments detailed [5][7] Industry Positioning - Quantum eMotion aims to meet the growing demand for affordable cybersecurity solutions for connected devices, leveraging its patented Quantum Random Number Generator technology [8] - The company targets sectors such as Financial Services, Healthcare, Blockchain Applications, Cloud-Based IT Security, Government Networks, and Quantum Cryptography [9]

Core Insights - F3 Uranium Corp. has entered into a digital marketing services agreement with Connect 4 Marketing Ltd. to enhance its marketing efforts in English and German markets [1][2] - The agreement spans 12 months starting November 28, 2025, with an option for extension [2] - The total cost of the agreement can reach up to $500,000 CAD, including an initial upfront payment of $100,000 CAD [3] Company Overview - F3 Uranium Corp. is focused on uranium exploration, particularly in the high-grade JR Zone of its Patterson Lake North Project located in the Western Athabasca Basin [5] - The company holds three properties in the Athabasca Basin: Patterson Lake North, Minto, and Broach, which is known for hosting some of the world's largest high-grade uranium deposits [5]

Core Viewpoint - Platinum Group Metals Ltd. reported its financial results for the fiscal year ended August 31, 2025, highlighting the advancement of the Waterberg Project, which is expected to be one of the largest and lowest-cost underground platinum group metals mines globally [1][20]. Financial Results - The company incurred a net loss of $4.54 million for the fiscal year, slightly improved from a net loss of $4.61 million in the previous year [16]. - General and administrative expenses increased to $3.66 million from $3.42 million year-over-year [16]. - Share-based compensation decreased to $1.19 million from $1.36 million [16]. - The foreign exchange gain was $95 thousand, compared to $4 thousand in the previous year, primarily due to the U.S. Dollar's appreciation against the Canadian Dollar [16]. Project Ownership and Structure - As of August 31, 2025, the Waterberg Project is owned by Waterberg JV Resources (Pty) Ltd., with Platinum Group holding a 37.32% interest [4]. - The ownership structure includes Mnombo (26.0%), HJ Platinum Metals Company Ltd. (21.95%), and Impala Platinum Holdings Ltd. (14.73%) [4]. - HJ Platinum Metals Company Ltd. was established in 2023 to hold and fund future equity interests in the Waterberg Project [5]. Recent Developments - On September 17, 2025, Waterberg JV Co. approved a sixth stage of work budgeted at Rand 92.1 million (approximately $5.11 million) for fiscal year 2026 [7]. - A non-brokered private placement of common shares was closed on May 29, 2025, raising $1.0 million, allowing Hosken Consolidated Investments Limited to maintain a 26% interest in the company [8]. - An interim budget of Rand 42 million (approximately $2.27 million) was approved on February 18, 2025, for the continuation of work programs [9]. Project Expenditures - Total expenditures on the Waterberg Project for the year ended August 31, 2025, were approximately $2.0 million, down from $3.0 million in the previous year [19]. - Accumulated net costs capitalized to the Waterberg Project reached $49.2 million as of August 31, 2025, compared to $47.0 million the previous year [19]. Future Outlook - The primary business objective is to advance the Waterberg Project to a development and construction decision [20]. - The company is assessing commercial alternatives for mine development financing and concentrate offtake [22]. - Discussions are ongoing with South African integrated producers regarding formal concentrate offtake arrangements [22]. Environmental, Social, and Governance (ESG) - The company received a BBB score in its 2025 ESG disclosure report from Digbee Ltd., indicating a commitment to improving ESG performance [26].

Core Insights - Hemostemix Inc. has initiated its strategy to acquire cardiology practices, starting with two prominent cardiologists in the Dominican Republic, Dr. Roberto Manuel Fernandez-de-Castro and Dr. Hector Rosario Figueroa, for 2,000,000 shares each [1][11] - The long-term strategy aims to integrate profitable medical practices to enhance the commercialization of ACP-01 treatments, creating a sustainable patient flow for the company [2][6] - The two cardiologists have extensive experience, having treated over 200 patients with ACP-01, positioning them as key figures in the company's expansion efforts [3][7] Company Strategy - The acquisition of these practices is part of a broader plan to establish a clinical and commercial presence internationally, with a focus on patient treatment flow and increasing practitioner engagement [2][6] - Hemostemix aims to replicate its business model across various markets, including Florida, Puerto Rico, and Canada, leveraging the expertise of the acquired cardiologists [6][7] Clinical Expertise - Dr. Fernandez-de-Castro and Dr. Figueroa will contribute their expertise in treating various cardiovascular conditions, including Angina, Ischemic and Dilated Cardiomyopathy, Congestive Heart Failure, Peripheral Arterial Disease, Chronic Limb-Threatening Ischemia, and Vascular Dementia [5][4] - Their established reputations and patient bases in the Dominican Republic are expected to facilitate the implementation of ACP-01 therapy [4][5] Financial Aspects - The TSXV has approved an extension for a non-brokered private placement, allowing Hemostemix to raise funds at $0.11 per unit, with total gross proceeds of $461,230 raised to date [8] - Each unit consists of one common share and one warrant, with the potential for additional shares to be acquired at $0.15 per share [8] Company Background - Hemostemix is an autologous stem cell therapy platform company, recognized for its development of VesCell™ (ACP-01), which has shown promising results in clinical studies for various cardiovascular diseases [9] - The company has completed seven clinical studies involving 318 subjects, demonstrating the safety and efficacy of ACP-01 [9]

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of investors who purchased securities of Perrigo Company plc during the specified Class Period, highlighting potential compensation opportunities for affected investors [2][3]. Group 1: Class Action Details - The class action lawsuit pertains to securities purchased between February 27, 2023, and November 4, 2025, and a lead plaintiff must be appointed by January 16, 2026 [2][4]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3]. Group 2: Reasons for the Lawsuit - The lawsuit alleges that Perrigo made materially false and misleading statements regarding its infant formula business, which suffered from significant underinvestment and required substantial capital expenditures [6]. - It is claimed that there were significant manufacturing deficiencies in Perrigo's infant formula facility, leading to overstated financial results, including earnings and cash flow [6]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time and being ranked No. 1 for settlements in 2017 [5]. - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [5].

Core Points - Rosen Law Firm is encouraging investors of Marex Group plc who incurred losses exceeding $100,000 during the Class Period from May 16, 2024, to August 5, 2025, to secure legal counsel before the December 8, 2025, deadline for lead plaintiff applications [1][2]. Group 1: Legal Action Details - Investors who purchased Marex securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors can visit the provided link or contact the law firm directly for more information [3][6]. - The lawsuit alleges that Marex made materially false and misleading statements, including selling over-the-counter financial instruments to itself and inconsistencies in financial statements, which led to investor damages when the truth was revealed [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].